Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting.
Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021.
Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
You may not be if
Incomplete medical history
Clareo Health | Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
